Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 15/20 | 0.86 |
| ▸ | MMP1 | P03956 | 3/20 | 0.86 |
| ▸ | PSEN1 | P49768 | 2/20 | 0.86 |
| ▸ | PSEN2 | P49810 | 2/20 | 0.86 |
| ▸ | APH1B | Q8WW43 | 2/20 | 0.86 |
| ▸ | NCSTN | Q92542 | 2/20 | 0.86 |
| ▸ | APH1A | Q96BI3 | 2/20 | 0.86 |
| ▸ | PSENEN | Q9NZ42 | 2/20 | 0.86 |
| ▸ | MMP2 | P08253 | 1/20 | 0.86 |
| ▸ | MMP7 | P09237 | 1/20 | 0.86 |
| ▸ | MMP10 | P09238 | 1/20 | 0.86 |
| ▸ | MMP9 | P14780 | 1/20 | 0.86 |
| ▸ | MMP13 | P45452 | 1/20 | 0.86 |
| ▸ | MMP14 | P50281 | 1/20 | 0.86 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.86 |
| ▸ | MMP3 | P08254 | 2/20 | 0.53 |
| ▸ | NPY1R | P25929 | 1/20 | 0.49 |
| ▸ | SRC | P12931 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6094611 | 1.00 | APP (0.86) | APPMMP1PSEN1PSEN2APH1B | |
| SCHEMBL6859558 | 1.00 | APP (0.86) | APPMMP1PSEN1PSEN2APH1B | |
| SCHEMBL311595 | 1.00 | APP (0.86) | APPMMP1PSEN1PSEN2APH1B | |
| SCHEMBL13934568 | 1.00 | APP (0.86) | APPMMP1PSEN1PSEN2APH1B | |
| SCHEMBL4482305 | 0.97 | APP (0.86) | APPMMP1PSEN1PSEN2APH1B | |
| SCHEMBL13934576 | 0.97 | APP (0.86) | APPMMP1PSEN1PSEN2APH1B | |
| SCHEMBL6166785 | 0.97 | APP (0.86) | APPMMP1PSEN1PSEN2APH1B | |
| SCHEMBL4487283 | 0.95 | APP (0.79) | APPMMP1PSEN1PSEN2APH1B | |
| SCHEMBL14348193 | 0.94 | APP (0.88) | APPMMP1PSEN1PSEN2APH1B | |
| SCHEMBL13920936 | 0.94 | APP (0.88) | APPMMP1PSEN1PSEN2APH1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2408450-B1 | ALPHA-(N-SULFONAMIDO)ACETAMIDE COMPOUND AS AN INHIBITOR OF BETA AMYLOID PEPTIDE PRODUCTION | BRISTOL MYERS SQUIBB CO (US) | 2013-03-13 | — | — | EP | disclosed |
| EP-2471769-A1 | Process for preparing a benzonitrile derivative | Bristol-Myers Squibb Company (US) | 2012-07-04 | — | — | EP | disclosed |
| US-8093276-B2 | Alpha-(N-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-01-10 | — | — | US | disclosed |
| EP-2295417-A1 | Novel intermediates useful for preparing alpha-(n-sulfonamido)acetamide compound | Bristol-Myers Squibb Company (US) | 2011-03-16 | — | — | EP | disclosed |
| EP-2205575-B1 | A NOVEL ALPHA-(N-SULFONAMIDO)ACETAMIDE COMPOUND AS AN INHIBITOR OF BETA AMYLOID PEPTIDE PRODUCTION | BRISTOL MYERS SQUIBB CO (US) | 2011-03-16 | — | — | EP | disclosed |
| US-20090227642-A1 | NOVEL ALPHA-(N-SULFONAMIDO)ACETAMIDE COMPOUND AS AN INHIBITOR OF BETA AMYLOID PEPTIDE PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY | 2009-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227642-A1 | NOVEL ALPHA-(N-SULFONAMIDO)ACETAMIDE COMPOUND AS AN INHIBITOR OF BETA AMYLOID PEPTIDE PRODUCTION | APP, BACE1, APBA1 | APP 1/4885MMP1 2096/4885PSEN1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.